Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced pancreatic cancer – real world data from the NORPACT-2 study-Reference-Cited by-同舟云学术

Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced pancreatic cancer – real world data from the NORPACT-2 study

Published:2024-07-03 Issue:9 Volume:59 Page:1093-1096
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Farnes Ingvild¹²,Lund-Iversen Marius³,Aabakken Lars²⁴,Verbeke Caroline²⁵,Labori Knut Jørgen¹²

Affiliation:

1. Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway

2. Institute of Clinical Medicine, University of Oslo, Oslo, Norway

3. Department of Pathology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway

4. Section of Gastroenterology, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway

5. Department of Pathology, Oslo University Hospital, Rikshospitalet, Oslo, Norway

Funder

South-Eastern Norway Regional Health Authority

Norwegian Cancer Society

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2024.2373115

Reference20 articles.

1. Pancreatic cancer – the past, the present, and the future

2. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

3. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

4. Nationellt vårdprogram bukspottkörtelcancer. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/bukspottkortelcancer/vardprogram/.

5. Kliniske retningslinjer for pancreascancer. Available from: https://www.dmcg.dk/Kliniske-retningslinjer/kliniske-retningslinjer-opdelt-paa-dmcg/pancreas-cancer/.